Compile Data Set for Download or QSAR
maximum 50k data
Found 2566 with Last Name = 'fraley' and Initial = 'me'
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362044(US10272077, Example 4 | US9833448, Example 4)
Affinity DataKi:  0.0150nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362044(US10272077, Example 4 | US9833448, Example 4)
Affinity DataKi:  0.0150nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362171(US10272077, Example 5 | US9833448, Example 5)
Affinity DataKi:  0.0170nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362171(US10272077, Example 5 | US9833448, Example 5)
Affinity DataKi:  0.0170nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362174(US9833448, Example 17)
Affinity DataKi:  0.0550nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM381649(US10272077, Example 17)
Affinity DataKi:  0.0550nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM361594(US10272077, Example 1 | US9833448, Example 1)
Affinity DataKi:  0.0670nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM361595(US10272077, Example 3 | US9833448, Example 3)
Affinity DataKi:  0.0670nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM361594(US10272077, Example 1 | US9833448, Example 1)
Affinity DataKi:  0.0670nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM361595(US10272077, Example 3 | US9833448, Example 3)
Affinity DataKi:  0.0670nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362175(US10272077, Example 26 | US9833448, Example 26)
Affinity DataKi:  0.0930nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362175(US10272077, Example 26 | US9833448, Example 26)
Affinity DataKi:  0.0930nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362176(US10272077, Example 30 | US9833448, Example 30)
Affinity DataKi:  0.140nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362176(US10272077, Example 30 | US9833448, Example 30)
Affinity DataKi:  0.140nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362177(US10272077, Example 31 | US9833448, Example 31)
Affinity DataKi:  0.170nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362177(US10272077, Example 31 | US9833448, Example 31)
Affinity DataKi:  0.170nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362172(US10272077, Example 6 | US9833448, Example 6)
Affinity DataKi:  0.210nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362172(US10272077, Example 6 | US9833448, Example 6)
Affinity DataKi:  0.210nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362173(US10272077, Example 11 | US9833448, Example 11)
Affinity DataKi:  0.25nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362173(US10272077, Example 11 | US9833448, Example 11)
Affinity DataKi:  0.25nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362180(US10272077, Example 8 from US 2010/0179166 | US983...)
Affinity DataKi:  1.70nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362180(US10272077, Example 8 from US 2010/0179166 | US983...)
Affinity DataKi:  1.70nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362179(US10272077, Example 9 from U.S. Pat. No. 7,390,798...)
Affinity DataKi:  1.90nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362179(US10272077, Example 9 from U.S. Pat. No. 7,390,798...)
Affinity DataKi:  1.90nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112665(US8623863, 2-8)
Affinity DataKi:  3.30nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112672(US8623863, 3-5)
Affinity DataKi:  3.80nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112669(US8623863, 3-2)
Affinity DataKi:  4.20nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362181(US10272077, Example 32 from U.S. Pat. No. 7,390,79...)
Affinity DataKi:  4.30nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362181(US10272077, Example 32 from U.S. Pat. No. 7,390,79...)
Affinity DataKi:  4.30nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112674(US8623863, 3-8)
Affinity DataKi:  5.10nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362178(US10272077, Example 8 from U.S. Pat. No. 7,390,798...)
Affinity DataKi:  7.40nMAssay Description:The binding of 125I-CGRP to receptors in SK-N-MC cell membranes was carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcitonin gene-related peptide type 1 receptor(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM362178(US10272077, Example 8 from U.S. Pat. No. 7,390,798...)
Affinity DataKi:  7.40nMAssay Description:Cells were resuspended in DMEM/F12 (Hyclone) supplemented with 1 g/L BSA and 300 μM isobutyl-methylxanthine. Cells were then plated in a 384-wel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112664(US8623863, 1-8)
Affinity DataKi:  7.90nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112665(US8623863, 2-8)
Affinity DataKi:  8.70nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112674(US8623863, 3-8)
Affinity DataKi:  8.70nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112667(US8623863, 2-10)
Affinity DataKi:  9.70nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112670(US8623863, 3-3)
Affinity DataKi:  10nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112666(US8623863, 2-9)
Affinity DataKi:  10nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112675(US8623863, 4-9)
Affinity DataKi:  11nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112671(US8623863, 3-4)
Affinity DataKi:  13nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112673(US8623863, 3-6)
Affinity DataKi:  14nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112664(US8623863, 1-8)
Affinity DataKi:  15nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112668(US8623863, 2-11)
Affinity DataKi:  28nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112669(US8623863, 3-2)
Affinity DataKi:  29nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112675(US8623863, 4-9)
Affinity DataKi:  39nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112670(US8623863, 3-3)
Affinity DataKi:  42nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112666(US8623863, 2-9)
Affinity DataKi:  50nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112672(US8623863, 3-5)
Affinity DataKi:  73nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112671(US8623863, 3-4)
Affinity DataKi:  110nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112667(US8623863, 2-10)
Affinity DataKi:  150nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 2566 total ) | Next | Last >>
Jump to: